Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump‐treated type 1 diabetes
| Autor: | Dorte Vistisen, Henrik U. Andersen, Kirsten Nørgaard, Jens-Erik Beck Jensen, Sten Madsbad, Sjudur Frodi Olsen, Thorhallur I. Halldorsson, Christian Seerup Frandsen, Thomas F. Dejgaard, Signe Schmidt |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Insulin pump medicine.medical_specialty type 1 diabetes Endocrinology Diabetes and Metabolism Insulins Overweight Added sugar insulin pump therapy Placebo Endocrinology Double-Blind Method Weight loss Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Glycated Hemoglobin body composition liraglutide Type 1 diabetes business.industry Liraglutide medicine.disease Diabetes Mellitus Type 1 Treatment Outcome Diabetes Mellitus Type 2 Body Composition Lean body mass Drug Therapy Combination weight loss medicine.symptom Sugars business food frequency medicine.drug |
| Zdroj: | Schmidt, S, Frandsen, C S, Dejgaard, T F, Vistisen, D, Halldorsson, T, Olsen, S F, Jensen, J-E B, Madsbad, S, Andersen, H U & Nørgaard, K 2022, ' Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes ', Diabetes, Obesity and Metabolism, vol. 24, no. 2, pp. 212-220 . https://doi.org/10.1111/dom.14567 |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/dom.14567 |
| Popis: | AimsTo present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump-treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide-associated weight loss.Materials and methodsA 26-week randomized placebo-controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump-treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)- and body weight-reducing effects. For secondary outcome analysis, dual X-ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire-based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide-induced changes in body composition and food intake.ResultsTotal fat and lean body mass decreased in liraglutide-treated participants (fat mass −4.6 kg [95% confidence interval {CI} −5.7; −3.5], P ConclusionsLiraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text